Metabolic stability assay in hepatocytes

Aim: Screening of in vitro metabolic stability of test compound in cryopreserved human and preclinical species hepatocytes.

Background information: Metabolism is the enzymatic modification of drugs to enable their excretion. Although metabolites are typically inactive, some metabolites may be pharmacologically active.

The liver is the main site of drug metabolism in the body. Unlike liver microsomes, hepatocytes contain both phase I and phase II compound metabolising enzymes, which are present in the intact cell.

Metabolic stability is assessed by measuring test compound depletion with time. Results can be used to assess interspecies differences in metabolism and in vitro intrinsic clearance, which in turn, can be used to predict in vivo hepatic clearance.

Compound requirement: 50 µl of 10 mM DMSO solution

Turnaround time: 4 weeks / 2 compounds / 5 species

Experimental design:

  • Test compound concentration: 1 µM (variable on request)
  • Number of replicates: 2
  • Number of cells: 1 million/ml
  • Time points: 0, 30, 60, 90 and 120 min ± cells, and negative control
  • Positive control: compound with known stability
  • Analytical method: UPLC-MS/MS

Delivered results:

  • In vitro intrinsic clearance
  • % test compound remaining at each time point relative to time 0

Dear colleagues, collaborators, and friends,

After more than 30 years of shared endeavours, in which we have grown personally and professionally, and with our emotions on the surface, we announce the closure of our company. We have travelled together through ups and downs, celebrated successes and overcome challenges as a team.

We extend our deepest gratitude to each of you for your dedication, passion, and commitment to a shared goal: discovering new treatments for the benefit and well-being of patients.

As we bid farewell, let’s cherish the memories we’ve created, the bonds we’ve formed, and the impact we’ve made together. Though our paths may diverge, the spirit of collaboration and camaraderie that defines our community will always endure.

We leave proud of the work accomplished and thank you for being an integral part of our journey, wishing you success in all your future challenges.

With heartfelt appreciation,

Welab’s team

We are proud to announce that Welab is partner of this new EU funded project.

In collaboration with 12 partners from 6 countries, Welab Barcelona is establishing the Antivirus Pandemic Preparedness EuropeAn pLatform (APPEAL), a European research initiative aimed at enhancing preparedness for future pandemics. This EU funded collaboration will establish a comprehensive program for the development of broad-spectrum antiviral drugs within a five year time frame ensuring drug affordability and accessibility to low income countries.
Link to the press release: https://lnkd.in/d-jmV2CS